drugset / Trial / NCT03941405

Albumin for Management of Hypervolemic Hyponatremia (AlbuCAT)

NCT03941405

Phase 2 Completed 52 enrolled Fundacion Clinic per a la Recerca Biomédica
RandomizedParallel-groupOpen-labelTreatment

Summary

resolution of hyponatremia, defined as an increase in serum sodium of more than 5 mEq/L with a final value \> 130 mEq/L, maintained for at least 48 consecutive hours during the 10-day treatment period

Timeline

Start
2020-02-01
Primary completion
2024-12-28
Completion
2025-01-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Albumin Protein / enzyme biologic 40 g

Indications